Literature DB >> 31242780

A review of IVF in PCOS patients at risk of ovarian hyperstimulation syndrome.

Nisha Thakre1, Roy Homburg1.   

Abstract

Introduction: Polycystic ovarian syndrome (PCOS) is the commonest endocrinopathy affecting women in the reproductive age group. The prevalence may vary from 8.7% to 17% depending on the clinical criteria used. PCOS women having IVF presents multiple challenges ranging from a poor to an exaggerated response, poor egg to follicle ratio, poor fertilisation, poor blastocyst conversion and ovarian hyperstimulation syndrome. Ovarian stimulation should be planned with attention paid to the AMH, antral follicle count and LH in particular. The dose of the stimulating gonadotrophin should be planned to achieve an optimal response during a GnRH antagonist cycle. Areas covered: We obtained evidence from chapters, case studies, practice committee reports, randomised controlled trials, Cochrane and systematic reviews. Expert opinion: IVF for PCOS is challenging. We have reached an understanding of careful low dose stimulation of ovaries considering AMH and antral follicle count. PCOS women should have the GnRH agonist trigger and freezing of embryos. Segmentation of an IVF cycle in PCOS woman makes it safer and has better outcome.

Entities:  

Keywords:  GnRH agonist trigger; IVF; PCOS; segmentation of IVF

Mesh:

Substances:

Year:  2019        PMID: 31242780     DOI: 10.1080/17446651.2019.1631797

Source DB:  PubMed          Journal:  Expert Rev Endocrinol Metab        ISSN: 1744-6651


  8 in total

1.  Ovarian stimulation outcomes among transgender men compared with fertile cisgender women.

Authors:  Hadar Amir; Iris Yaish; Nivin Samara; Joseph Hasson; Asnat Groutz; Foad Azem
Journal:  J Assist Reprod Genet       Date:  2020-07-28       Impact factor: 3.412

2.  Integrated Network Pharmacology and Clinical Study to Reveal the Effects and Mechanisms of Bushen Huoxue Huatan Decoction on Polycystic Ovary Syndrome.

Authors:  Jie Ding; Mei Shanshan; Cai Mengcheng; Zhang Danying; Yu Jin
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-13       Impact factor: 2.650

3.  Correlation between steroid levels in follicular fluid and hormone synthesis related substances in its exosomes and embryo quality in patients with polycystic ovary syndrome.

Authors:  Li Yu; Miao Liu; Zhenxin Wang; Te Liu; Suying Liu; Beili Wang; Baishen Pan; Xi Dong; Wei Guo
Journal:  Reprod Biol Endocrinol       Date:  2021-05-17       Impact factor: 5.211

4.  Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol.

Authors:  Ting-Chi Huang; Mei-Zen Huang; Kok-Min Seow; Ih-Jane Yang; Song-Po Pan; Mei-Jou Chen; Jiann-Loung Hwang; Shee-Uan Chen
Journal:  Sci Rep       Date:  2021-11-23       Impact factor: 4.379

5.  Clinical Pregnancy and Incidence of Ovarian Hyperstimulation Syndrome in High Ovarian Responders Receiving Different Doses of hCG Supplementation in a GnRH-Agonist Trigger Protocol.

Authors:  Xiuzhen Shen; Qinjie Yang; Lanfang Li; Wenhao Lu
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-25       Impact factor: 2.629

6.  Machine Learning-Based Modeling of Ovarian Response and the Quantitative Evaluation of Comprehensive Impact Features.

Authors:  Liu Liu; Fujin Shen; Hua Liang; Zhe Yang; Jing Yang; Jiao Chen
Journal:  Diagnostics (Basel)       Date:  2022-02-14

7.  Assessment of prevalence, knowledge of polycystic ovary syndrome and health-related practices among women in klang valley: A cross-sectional survey.

Authors:  Jia Ean Goh; Muhammad Junaid Farrukh; Fazlollah Keshavarzi; Chuan Sheng Yap; Zikria Saleem; Muhammad Salman; Diana Laila Ramatillah; Khang Wen Goh; Long Chiau Ming
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-29       Impact factor: 6.055

Review 8.  Spontaneous ovarian hyperstimulation syndrome in a nonpregnant female patient: a case report and literature review.

Authors:  Wei Chai; Hongyu He; Fei Li; Wenlei Zhang; Chao He
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.